Investors
& Media

NEW YORK, NY OCT. 25, 2005 - Manhattan Pharmaceuticals, Inc. (AMEX: MHA) announced that Douglas Abel, President and Chief Executive Officer, will present at the PIPEs Conference 2005 on October 26 and 27 at the Waldorf-Astoria Hotel in New York City. Mr. Abel will provide a corporate overview, including a review of the Company's lead product candidate Oleoyl-estrone (OE), an experimental, orally administered small molecule in development for the treatment of obesity.

The presentations will take place at 2:30 p.m. and 3:00 p.m. EDT on Wednesday, October 26 and at 2:30 p.m. EDT on Thursday, October 27.The PIPEs conference is a prominent investment community event that features presentations from leading industry professionals. Information about the conference can be found at www.thepipesconference.com.

For more information on Manhattan Pharmaceuticals and their product candidates please visit the company's website at www.manhattanpharma.com.

About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc. (AMEX: MHA), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (http://www.manhattanpharma.com)

Contact
Nicholas J. Rossettos, CPA
Chief Financial Officer
Manhattan Pharmaceuticals, Inc.
212/582 3950

Thomas Redington
Redington, Inc.
203/222-7399
212/926-1733